Widening for clopidogrel BE study [Outliers]

posted by Loky do – Egypt, 2021-06-16 17:08 (340 d 18:07 ago) – Posting: # 22420
Views: 1,506

» You linked the EMA Q&A where it is stated unequivocally:
» Under these circumstances, the widening of 90% confidence intervals for Cmax is not recommended.

Ok, in my case, the study fails as per EMA guidance, but if we used the FDA method for calculations it passes, regarding a drug as clopidogrel with many therapeutic issues, could it be accepted by different authorities, considering FDA guidelines (sponsor requests to submit an appeal to authorities to use calculations as per FDA guidelines as the protocol uses EMA guidance for statistical calculations)?
thanks

Complete thread:

UA Flag
Activity
 Admin contact
22,091 posts in 4,630 threads, 1,567 registered users;
online 13 (1 registered, 12 guests [including 4 identified bots]).
Forum time: Monday 11:15 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5